Brief: OncoSec Is Encouraged After FDA Meeting To Discuss Proposed Neoadjuvant Melanoma Clinical Program
16/05/2023 13:28
May 16 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC IS ENCOURAGED AFTER FDA MEETING TO DISCUSS
PROPOSED
NEOADJUVANT MELANOMA CLINICAL PROGRAM
* ONCOSEC MEDICAL INC - TODAY ANNOUNCED A TYPE C MEETING
HELD
WITH FDA ON MAY 15
* ONCOSEC MEDICAL - TALK WITH FDA FOLLOWS RELEASE OF
INTERIM DATA
FROM ONGOING INVESTIGATOR-SPONSORED TRIAL IN COMBINATION WITH
INTRAVENOUS NIVOLUMAB
Source text for Eikon: ID:nPn1L1P5ba
Further company coverage: ONCS.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq